Search - Université de Rennes Access content directly

Filter your results

24 Results
Author: personID (integer) : 762201

A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma

Bertrand Coiffier , Catherine Thieblemont , Sophie de Guibert , Jehan Dupuis , Vincent Ribrag et al.
British Journal of Haematology, 2016, 173 (5), pp.722-730. ⟨10.1111/bjh.13992⟩
Journal articles hal-01295660v1

Management and outcome of primary CNS lymphoma in the modern era: An LOC network study

Caroline Houillier , Carole Soussain , Hervé Ghesquières , Pierre Soubeyran , Olivier Chinot et al.
Neurology, 2020, 94 (10), pp.e1027-e1039. ⟨10.1212/WNL.0000000000008900⟩
Journal articles hal-02442415v1

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network

Sophie Langner-Lemercier , Caroline Houillier , Carole Soussain , Hervé Ghesquières , Olivier Chinot et al.
Neuro-Oncology, 2016, 18 (9), pp.1297-1303. ⟨10.1093/neuonc/now033⟩
Journal articles hal-01290413v1

A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Vincent Ribrag , Jehan Dupuis , Herve Tilly , Franck Morschhauser , Fabrice Laine et al.
Clinical Cancer Research, 2014, 20 (1), pp.213--220. ⟨10.1158/1078-0432.CCR-13-0580⟩
Journal articles hal-01068681v1

Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA

Roch Houot , Carole Soussain , Hervé Tilly , Corinne Haioun , Catherine Thieblemont et al.
Annals of Oncology, 2016, 27 (7), pp.1349-50. ⟨10.1093/annonc/mdw138⟩
Journal articles hal-01295653v1
Image document

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

Roberta Di Blasi , Steven Le Gouill , Emmanuel Bachy , Guillaume Cartron , David Beauvais et al.
Blood, 2022, 140 (24), pp.2584-2593. ⟨10.1182/blood.2022016945⟩
Journal articles hal-03903472v1

Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma

Cédric Ménard , Delphine Rossille , Joelle Dulong , Tien-Tuan Nguyen , Ilenia Papa et al.
Blood Advances, 2021, 5 (8), pp.2063-2074. ⟨10.1182/bloodadvances.2020003774⟩
Journal articles hal-03267824v1

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

Ciara L. Freeman , Franck Morschhauser , Laurie Sehn , Mark Dixon , Richard Houghton et al.
Blood, 2015, 126 (24), pp.2646--2649. ⟨10.1182/blood-2015-09-670802⟩
Journal articles hal-01275480v1

Performance of CT Compared with F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma

Fatima-Zohra Mokrane , Aiping Chen , Lawrence H Schwartz , Franck Morschhauser , Apasia Stamatoullas et al.
Radiology, 2020, 295 (3), pp.651-661. ⟨10.1148/radiol.2020192056⟩
Journal articles hal-02569415v1

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.

Emilie Reboursiere , Fabien Le Bras , Charles Herbaux , Emmanuel Gyan , Aline Clavert et al.
Oncotarget, 2016, 7 (51), pp.85573-85583. ⟨10.18632/oncotarget.10764⟩
Journal articles hal-01475957v1
Image document

Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study

Franck Morschhauser , Kamal Bouabdallah , Stephan Stilgenbauer , Catherine Thieblemont , Sophie de Guibert et al.
Journal articles hal-02635130v1
Image document

Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group

Christophe Bonnet , Jehan Dupuis , Hervé Tilly , Thierry Lamy , Christophe Fruchart et al.
Cancers, 2022, 14 (7), pp.1761. ⟨10.3390/cancers14071761⟩
Journal articles hal-03660656v1
Image document

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

Vincent Ribrag , Serge Koscielny , Jacques Bosq , Thibaut Leguay , Olivier Casasnovas et al.
The Lancet, 2016, 387 (10036), pp.2402 - 2411. ⟨10.1016/S0140-6736(15)01317-3⟩
Journal articles inserm-01419476v1
Image document

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study.

Mira Tout , Olivier Casasnovas , Michel Meignan , Thierry Lamy , Franck Morschhauser et al.
Blood, 2017, 129 (19), pp.2616-2623. ⟨10.1182/blood-2016-10-744292⟩
Journal articles hal-01547802v1

Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC

Loic Ysebaert , Roch Houot , Ibrahim Yakoub-Agha , Franck Morschhauser , Charles Herbaux et al.
Blood, 2015, 126 (23), pp.3979-3979
Journal articles hal-01290424v1

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

Guillaume Cartron , Sophie de Guibert , Marie-Sarah Dilhuydy , Franck Morschhauser , Veronique Leblond et al.
Blood, 2014, 124 (14), pp.2196--2202. ⟨10.1182/blood-2014-07-586610⟩
Journal articles hal-01147035v1
Image document

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma a phase II LYSA study

Roch Houot , Guillaume Cartron , Fontanet Bijou , Sophie de Guibert , Gilles A Salles et al.
Leukemia, 2019, 33 (3), pp.776-780. ⟨10.1038/s41375-018-0282-y⟩
Journal articles hal-01903056v1
Image document

Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies

Laurent Dercle , Fatima-Zohra Mokrane , Jean Marc Schiano de Colella , Apasia Stamatoullas , Franck Morschhauser et al.
European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 (6), pp.1391-1392. ⟨10.1007/s00259-019-04310-x⟩
Journal articles hal-02119287v1

Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program

Aurore Perrot , Hélène Monjanel , Reda Bouabdallah , Philippe Quittet , Clémentine Sarkozy et al.
Journal articles hal-01259439v1

NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment

Dang-Nghiem Vo , Catherine Alexia , Nerea Allende-Vega , Franck Morschhauser , Roch Houot et al.
OncoImmunology, 2018, 7 (4), pp.e1409322. ⟨10.1080/2162402X.2017.1409322⟩
Journal articles hal-01780378v1
Image document

Early F-FDG PET/CT response predicts survival in Relapsed/Refractory Hodgkin Lymphoma treated with Nivolumab

Aiping Chen , Fatima-Zohra Mokrane , Lawrence Schwartz , Franck Morschhauser , Apasia Stamatoullas et al.
Journal of Nuclear Medicine, 2020, 61 (5), pp.649-654. ⟨10.2967/jnumed.119.232827⟩
Journal articles hal-02364994v1
Image document

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.

Emmanuel Bachy , Roch Houot , Franck Morschhauser , Anne Sonet , Pauline Brice et al.
Haematologica, 2013, 98 (7), pp.1107-14. ⟨10.3324/haematol.2012.082412⟩
Journal articles hal-00933219v1
Image document

Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA

Steven Le Gouill , Hervé Ghesquieres , Lucie Obéric , Franck Morschhauser , Herve Tilly et al.
Blood, 2021, 137 (17), pp.2307-2320. ⟨10.1182/blood.2020008750⟩
Journal articles hal-03122586v1
Image document

Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study

Franck Morschhauser , Steven Le Gouill , Pierre Feugier , Sarah Bailly , Emmanuelle Nicolas-Virelizier et al.
The Lancet Haematology, 2019, 6 (8), pp.e429-e437. ⟨10.1016/S2352-3026(19)30089-4⟩
Journal articles hal-02586078v1